Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz - biospace.com
Why now
Thesis: Obesity and biotech catalysts drive sector sentiment
Catalyst to watch: Trial data and FDA decisions
Main risk: Competitive or safety setbacks
Why it matters
Novo's turnaround and weight-loss wins shape obesity-drug competition; Ultragenyx approval adds pipeline news.
Sources
- googlenews · news.google.com · 2026-09-23 10:18 UTC